Saturday 17 October 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.96
0.05
+2.62%
Follow XTLB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 10.20 | 7.72 | 5.72 | 4.68 | 2.52 | 10.24 | 3.40 | 3.00 | 3.08 | 2.28 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 34.20 | 18.80 | 15.76 | 11.00 | 13.60 | 26.76 | 12.00 | 6.16 | 19.96 | 10.28 | |||||
| People | |||||||||||||||
| People | Employees | 7 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.67 | — | |||||
| EBT | (3) | (1) | 3 | (1) | (3) | 0 | (1) | (2) | 0 | (1) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (3) | (1) | 3 | (1) | (3) | 0 | (1) | (2) | (1) | (7) | |||||
| Depreciation | 1 | 0 | — | — | 0 | 0 | 0 | — | 0 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (3.60) | (0.68) | 2.40 | (1.20) | (2.30) | 0.32 | (0.99) | (1.32) | (0.80) | (3.11) | |||||
| Cash flow | (2.53) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.24) | (0.11) | |||||
| Capex | (0.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | (2.62) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.25) | (0.11) | |||||
| Book value | 3.92 | 3.08 | 6.47 | 5.43 | 2.81 | 4.01 | 2.94 | 1.63 | 0.81 | (0.03) | |||||
| Shares, m | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | — | 5.63 | — | |||||
| P/B | — | — | — | — | — | — | — | — | 1.93 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 4.84 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (2.56) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (1) | ||||
| Capex | 0 | 0 | — | 0 | 0 | — | — | — | 0 | — | |||||
| Free cash flow | (2) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (1) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2 | 6 | 8 | 7 | 6 | 6 | 4 | 2 | (1) | 0 | ||||
| Total debt | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Net debt | (2) | (4) | (8) | (7) | (6) | (6) | (4) | (2) | (1) | 0 | |||||
| Shareholders’ equity | 3 | 4 | 8 | 7 | 4 | 5 | 4 | 2 | 5 | 0 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (61.03) | (16.27) | 39.39 | (17.06) | (43.08) | 6.63 | (24.95) | (53.90) | (18.71) | (159.91) | ||||
| ROIC | (630.17) | (2,433.59) | (247.81) | (208.83) | 0.00 | 0.00 | (197.84) | (223.42) | (10.93) | 0.00 | |||||
| ROE | (67.20) | (24.77) | 50.01 | (17.61) | (55.78) | 9.73 | (28.89) | (57.31) | (26.83) | (269.02) | |||||
Negative figures in brackets.
Fiscal years to Dec 2012 · latest quarter Sep 2014
Charts ten years each
XTL Biopharmaceuticals Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMRN IMMURON | $8.3M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| ADIL Adial Pharmaceuticals, Inc. | $8.3M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $8.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| SNTI Senti Biosciences, Inc. | $8.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $8.1M | — (loss-making) | — | −39.32% (below 0%: shrinking) | n/m | +46.78% (above 0%: growing) | 0.00% | 0.00% | |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $8.1M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $8.0M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $7.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | Compare |
| APRE Aprea Therapeutics, Inc. | $7.8M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $8.1M | — | — | −98.40% | — | −6.35% | 84.46% | 0.00% |
XTL Biopharmaceuticals Ltd. (XTLB) key facts
- XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, XTLB traded at $1.96, a market capitalization of $8.1 million.
- Return on equity was −269.0% and debt-to-equity -1.83.